SG Americas Securities LLC decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 17.9% during the 4th quarter, according to the company in its most recent disclosure with the ...

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%. Meanwhile ...

CRISPR-guided endonucleases were an obvious route, but for RNA, the options were few and imperfect. Cas13 proved useful for RNA knockdown, but it caused collateral damage to non-target RNA. Although ...

In July 2023, Sanofi expanded an existing partnership with Scribe Therapeutics to use its CRISPR-based gene-editing technology to develop both in vivo and ex vivo cancer cell therapies.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

View Full Profile. Learn about our Editorial Policies. “What’s significant about this is it’s taking CRISPR to that next step of what it can be used for, and in this case, it’s correcting mutations ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...